Zyla Life Sciences (fka ZCOR)

[Billybob_TX]

News: Non-dilutive grant funding from Danish government.

https://www.prnewswire.com/news-releases/egalet-received-a-grant-from-innobooster-to-develop-a-novel-application-of-guardian-technology-300559257.html

Egalet Received a Grant from InnoBooster to Develop a Novel Application of Guardian™ Technology

WAYNE, Pa., Nov. 20, 2017 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) (Egalet), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced the company was awarded a grant from InnoBooster to develop a novel oral delivery system using a new application of Egalet's Guardian Technology to develop products in therapeutic areas outside of pain.

"We believe the grant from InnoBooster demonstrates the breadth of applications of our Guardian Technology," said Karsten Lindhardt, Ph.D., chief scientific officer of Egalet. "This provides a fantastic opportunity for us to use a novel approach to potentially develop oral formulations of products that would normally be delivered via injection."

The grant provides non-dilutive funds to support the research project and will cover most of the external expenses needed to explore this opportunity into the pre-clinical stage of development.

About InnoBooster
InnoBooster is a fund under the Danish Growth Fund. The fund's objective is to promote growth and renewal for small and medium-sized enterprises in order to achieve a greater socio-economic return. Since 1992, The Danish Growth Fund has together with private investors co-financed growth in more than 6,600 Danish companies with a total commitment of more than DKK 20 billion. InnoBooster invests in promising ideas from start-ups. In 2017, InnoBooster will distrubute DKK 300 million. InnoBooster has a strong focus on innovative companies with the potential to create growth and jobs in Denmark.

About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO® ER (morphine sulfate) extended-release tablets for oral use —CII, developed using Egalet's proprietary Guardian™ Technology, OXAYDO® (oxycodone HCI, USP) tablets for oral use only —CII and SPRIX® (ketorolac tromethamine) Nasal Spray. Using Guardian Technology, Egalet is developing a pipeline of clinical-stage, product candidates for which we are seeking partners including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For full prescribing information on ARYMO ER, including the boxed warning and medication guide, please visit arymoer.com. For full prescribing information on SPRIX, including the boxed warning and medication guide, please visit sprix.com. For full prescribing information on OXAYDO, including the boxed warning and medication guide, please visit oxaydo.com.